Skip to Content
COVID-19 Response and Update

Amneal strengthens commitment in India as Co-CEO Chirag Patel leads the Healthcare and Pharmaceuticals Sector Working Group within the U.S.-India CEO Forum

Mumbai, India: Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced the company’s Co-founder and Co-CEO Chirag Patel’s appointment as U.S. Chair of the Healthcare and Pharmaceuticals Sector Working Group within the U.S.-India CEO Forum by U.S. Department of Commerce Secretary Gina M. Raimondo. Mr. Patel will join CEOs from a number of other industries in the Forum, which is being organized by the U.S. Department of Commerce and India Ministry of Commerce and Industry in New Delhi, India on March 10, 2023. The forum will bring CEOs and government officials from both countries together to share their vision on the growth opportunities between the United States and India.

Amneal Pharmaceuticals is a leading U.S.-based affordable medicines company with a longstanding R&D and manufacturing footprint in India. The company also recently expanded its presence with the initiation of its India commercial operations in October 2022.

“It is an honor for me to have been appointed by Secretary Raimondo to help lead this significant public-private endeavor on behalf of the healthcare and pharma sector. The deep roots and expanding investments by Amneal in both countries will be crucial in ensuring that patients in India, the United States, and elsewhere can get access to high-quality, affordable medicines. We have already invested over USD 500 million in India and continue to explore opportunities to extend partnerships with government and other stakeholders to deliver outcomes that address unmet medical needs. Through this forum, we look forward to strengthening economic partnerships while also working together to resolve critical business challenges faced by the healthcare/pharmaceutical industry across both rapidly growing countries ” said Chirag Patel, co-founder and co-CEO of Amneal Pharmaceuticals and Chair, Healthcare and Pharmaceuticals Sector Working Group, U.S.-India CEO Forum.

The CEO Forum is convened as a platform to allow private sector members to develop and provide recommendations to the Indian and U.S. governments and their senior officials that reflect private sector views, needs, concerns, and suggestions about the creation of an environment in which their respective private sectors can partner, thrive, and enhance bilateral commercial ties to expand trade and economy.

While Amneal continues its growth journey in the U.S. pharmaceutical industry, the company is deeply committed to expanding in India and has been strengthening its long-term investment in the country by:

  • Continuing its strong manufacturing presence in India with 9 facilities located across Ahmedabad, Hyderabad, Vishakhapatnam and Dahej.
  • In October 2022, the company started its commercial operations in India, focused on critical care business, and will be bringing to market an innovative portfolio for Ophthalmology, Oncology, Rare Diseases and CNS therapy areas.
  • Enhancing Indian R&D and manufacturing capabilities with investment of over $500 million since 2008, including the 2021 acquisition of Puniska Healthcare’ world-class injectables manufacturing facility and building a biopharmaceutics manufacturing capacity for India and global market.
  • Advancing and expanding a highly skilled R&D and manufacturing workforce of over 5,200 employees in India.
  • Maintaining Amneal’s foundational commitment to global quality manufacturing, providing world-class quality affordable medicines for improved patient outcomes in India.

Commemorating International Infection Prevention Week, P.D. Hinduja Hospital & MRC introduces the latest innovation in IV Infusion for the first time in Mumbai

Mumbai, India:  P.D. Hinduja Hospital & Medical Research Centre, Mahim is one of the leading institutes focusing its efforts to create awareness around the increasing trend and effective management of antimicrobial resistance (AMR). 

AMR also known as antimicrobial drug resistance, occurs when microorganisms such as bacteria, fungi etc.  change in such a way that the medications used to treat infections they cause are rendered ineffective. The World Health Organization (WHO) has declared AMR as one of the top 10 global health threats facing humanity. In 2019, The Lancet, a medical journal revealed that such resistance directly caused approximately 1,270,000 deaths worldwide.  India has one of the highest rates of AMR in the world, and according to government’s data released in 2019 these infections claim lives of close to 700,000 Indians annually.

AMR infections usually require the use of second line and third line treatments which can cause serious side-effects, such as organ failure and prolonged care and recovery, which could go on for months. The overall misuse and overuse of consumption of antibiotics which should only be used to treat the most serious infections like difficult-to-treat bacterial infections, and poor infection prevention and control, increase the spread of AMR. This rise in mortality and morbidity due to AMR infections is very alarming and the WHO and CDC have suggested that steps can and should be taken at all levels of society to reduce the impact and control the spread of resistance. Individuals, policy makers (government), healthcare professionals and the healthcare industry should all collectively contribute towards reducing the incidence of AMR infections.

“Stakeholders across India are working together to combat the alarming rate of antimicrobial resistance (AMR). While all precautions are taken, this challenge frequently extends beyond basic hospital hygiene and is rapidly becoming a global health concern. Adopting antimicrobial stewardship is a critical component of this, and one of the first steps that must be taken is to raise awareness and understanding of AMR through effective communication. At P.D Hinduja Hospital, we believe in bringing about a change in society and reaching greater heights in the service of humanity; and be at the forefront of bringing global quality medical solutions for the benefit of our patients. P.D. Hinduja Hospital & MRC is one of ICMR’s state center for antimicrobial stewardship and serves as a mentor for other institutes in the city.” commented, Mr. Joy Chakraborty, Chief Operating Officer, P.D Hinduja Hospital & MRC.

While there is no standardized region wise data on resistance rates, a few reports from hospitals and communities suggest that the overall resistance level is increasing by 5 to 10% every year for broad-spectrum antimicrobials which are highly misused.  A data analysis done by Indian Council for Medical Research (ICMR) between January 1 and December 31, 2021, found a sustained increase in drug-resistant pathogens, resulting in difficulty to treat certain infections with available medicines. This is a major concern because a resistant infection can spread to others and potentially impose huge costs to individuals and society. 

Mr. Shyamakant Giri, Managing Director & President, India Business and Emerging Markets, Amneal Healthcare said “As industry patrons, it is also our responsibility to develop or collaborate in developing platforms which help in preventing transmission of hospital infections and antimicrobial drug resistance. Uniport is a first-of-its-kind closed IV technology platform that is being manufactured by Amneal for India, in India. This will set new standards for delivery of IV solutions in the country. The INICC (International Nosocomial Infection Control Consortium), recommends use of closed infusion systems for administration of clinical treatments in hospitals. The government of India has taken several measures to control the rise of AMR in India, we look forward to partnering with stakeholders like P.D. Hinduja Hospital & MRC to reduce this burden by increasing access to this innovative technology for advanced care.”

Amneal Healthcare, subsidiary of NYSE-listed Amneal Pharmaceuticals, announced its commercial operations in India recently. Uniport is a safe IV with multipurpose single port bag offering a versatile and adaptive closed-infusion system. The Uniport bag introduces several technological advancements for optimum utilization like self-collapsibility, easy to squeeze, transparency for clear visibility. 

About P.D. Hinduja Hospital & Medical Research Centre: 

P.D. Hinduja Hospital & Medical Research Centre, part of the Hinduja Group, started as a clinic in 1951 and is today ranked as one of the leading multi-specialty tertiary care hospitals in the country. For over seven decades, this institute has worked to ensure that world-class healthcare delivery is provided to all. It currently has two units, one at Mahim with 400 beds and the other at Khar with 100 beds. Both the units are equipped with state-of-the-art infrastructure and has on-board some of the best nationally and internationally recognized doctors. P.D. Hinduja Hospital, Mahim has always been an early adopter of technology in delivery of care; being amongst the first few hospitals in the country to bring in the most advanced fully integrated Robotics System, Gama Knife, Digital Broadband MRI with ambient themes, True Beam Linear Accelerator and more. Quality care being the focus, it was amongst the early few hospitals that has been accredited and certified by NABH, CAP, and ISO. It continues to partner with leading International Institutes, latest being an arrangement with The Division of AIDS (NIAID, NIH), U.S.A, to establish a center of excellence for infectious disease research in India. P. D. Hinduja Hospital has consistently been bestowed with several Best Multi-Specialty Hospital awards by different industry bodies. In the Newsweek World’s Best Hospital Survey in 2020 and 2021, it was ranked No.1 in western India, 3rd amongst private hospitals in India and 6th amongst all hospitals in India. On the Charity front, the hospital provides free or concessional treatment to the needy and also runs the Serve with Passion rural health programme, under which free healthcare services are provided to the tribal areas in Maharashtra.

NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India Appoints Shyamakant Giri as Managing Director and President for India Business and Emerging Markets

Indian origin founders and Co-CEOs Chirag and Chintu Patel have invested significantly in
building scientific and manufacturing capabilities globally as well as India.

Mumbai, India: Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal), launches its commercial operations in India. To helm its India Commercial operations, Amneal has appointed Mr. Shyamakant Giri as Managing Director and President, India Business and Emerging Markets. Mr. Giri has over two decades of experience leading business divisions and strategic operations of leading Indian and multinational organizations. In this new role, he will be responsible for Amneal’s commercial expansion and growth in India, Africa, Gulf, CIS and South Asian markets.

Amneal Pharmaceuticals Inc. has a strong manufacturing and R&D footprint in India since 2008 with a focus on exports of key molecules and products thought its state-of-the-art world-class facilities across Ahmedabad, Dahej, Hyderabad and Vizag. With the commencement of Amneal’s India commercial operations, the company aims to serve the unmet medical needs, and extend its industry-leading reputation for high quality products at affordable prices.

Mr. Chirag and Chintu Patel, Co-Chief Executive Officers, Amneal said, “We are elated to be extending Amneal’s operations in India – a place close to our hearts. We look forward to working with the Indian stakeholders to make healthy possible through increased access to the latest innovations in essential medicines. Being a community-oriented firm, we have placed a specific emphasis on innovating products that address the market’s unmet needs. Onboarding an industry veteran like Giri, who shares our vision, will be a major impetus behind Amneal’s growth in India.”

Mr. Shyamakant Giri, Managing Director and President, India Business and Emerging Markets, Amneal Healthcare Pvt. Ltd., said, “I am honored to be a part of the Amneal family. A purpose driven company with a legacy of more than two decades, Amneal has been a rising leader in the U.S. pharmaceutical industry, and now is bringing access to global quality medical solutions in India today. With Amneal’s 20+ year legacy of strong R&D, expansive portfolio and know how, I believe we can deliver substantial value in addressing the country’s medical requirements and offer solutions to numerous health concerns.”

Amneal Pharmaceuticals Inc. is a New Jersey-based pharmaceutical company providing access to essential medicines. Delivering innovations in accessible medicines for patients and healthcare systems and building a strong foundation on honesty and integrity for the past 20+ years, the company has extended its portfolio from generics to specialty products, biosimilars and institutional injectables.